在健康参与者中对JADY101的1阶段研究
第1阶段,随机,双盲,安慰剂对照,单个上升剂量研究,以评估在健康志愿者中皮下施用的JADE101的安全性,耐受性,药代动力学和药效学
This is a Phase 1, first-in-human study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of JADE101 compared to placebo in healthy participants.
研究概览
详细说明
This is a single center, Phase 1, double-blind, placebo-controlled, randomized, first-in-human (FIH), single ascending dose study evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of JADE101 in healthy participants. The study will enroll approximately 32 healthy volunteers. JADE101 will be administered by a subcutaneous injection. The results of this study will help inform the dosing and frequency of dosing in future studies of JADE101.
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
-
Auckland、新西兰
- NZCR
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Healthy male or female participants 18-55 years of age, inclusive
- A body weight between 50-100 kg and a body mass index (BMI) between 18.0 - 32.0 kg/m2 (all inclusive) at screening
- Willing and able to comply with the study site stay, scheduled visits, and study procedures
- Willing and able to comply with using two methods of contraception (one being highly effective) and lifestyle requirements from admission through the end of the study
Exclusion Criteria:
- Harmful alcohol use
- Smoking/vaping or heavy tobacco use within 2 years prior to screening
- Known history of abuse of illicit drugs
- Nursing, lactating or pregnant, or who have plans to become pregnant during the study
- Known history of clinically significant disease
- Known history of immunodeficiency disorder
- History of clinically significant allergic reactions or hypersensitivity
学习计划
研究是如何设计的?
设计细节
- 主要用途:基础科学
- 分配:随机化
- 介入模型:顺序分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:JADE101
Subcutaneous (SC) injection of JADE101 |
JADE101 is supplied as sterile solution to be administered by SC injection. |
|
安慰剂比较:Placebo
Subcutaneous (SC) injection of placebo |
Placebo solution to be administered at a matching volume by SC injection. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Safety and Tolerability of Single Ascending Doses of JADE101 in Healthy Participants
大体时间:Day 1 through 48 weeks
|
Incidence of treatment-emergent adverse events |
Day 1 through 48 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Cmax
大体时间:Day 1 through 48 weeks
|
Maximum observed serum concentration |
Day 1 through 48 weeks
|
|
Tmax
大体时间:Day 1 through 48 weeks
|
Time to reach Cmax |
Day 1 through 48 weeks
|
|
AUClast
大体时间:Day 1 through 48 weeks
|
The area under the concentration-time curve from time zero to the time of the last observed quantifiable (non-zero) concentration |
Day 1 through 48 weeks
|
|
T1/2
大体时间:Day 1 through 48 weeks
|
Apparent first-order terminal elimination half-life |
Day 1 through 48 weeks
|
合作者和调查者
调查人员
- 研究主任:Li Li, MD、Jade Biosciences, Inc.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他研究编号
- JADE101-01
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.